Stryker Corporation vs Moderna

Side-by-side comparison of AI visibility scores, market position, and capabilities

Moderna leads in AI visibility (85 vs 74)
Stryker Corporation logo

Stryker Corporation

LeaderHealthcare Tech

Enterprise

Stryker (SYK) reported $22.6B revenue in FY2024, up 11% YoY. Top-3 global medical device company. Leader in surgical robotics (Mako), implants, and emergency equipment. HQ: Kalamazoo, MI.

AI VisibilityBeta
Overall Score
B74
Category Rank
#79 of 290
AI Consensus
53%
Trend
stable
Per Platform
ChatGPT
73
Perplexity
85
Gemini
78

About

Stryker Corporation is one of the world's largest medical technology companies, headquartered in Kalamazoo, Michigan. Founded in 1941 by Dr. Homer Stryker as an orthopedic device company, Stryker has expanded through innovation and acquisitions into a comprehensive medical device platform. The company reported revenues of $22.6B in FY2024, up 11% year-over-year, with a market capitalization of approximately $135B.

Full profile
Moderna logo

Moderna

LeaderHealthcare Tech

Enterprise

mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.

AI VisibilityBeta
Overall Score
A85
Category Rank
#23 of 290
AI Consensus
78%
Trend
up
Per Platform
ChatGPT
91
Perplexity
90
Gemini
89

About

Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.

Full profile

AI Visibility Head-to-Head

74
Overall Score
85
#79
Category Rank
#23
53
AI Consensus
78
stable
Trend
up
73
ChatGPT
91
85
Perplexity
90
78
Gemini
89
81
Claude
94
65
Grok
84

Key Details

Category
Enterprise
Enterprise
Tier
Leader
Leader
Entity Type
company
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.